ARCHIMED announced the closing of its acquisition of Esperion Therapeutics, a biopharmaceutical company that brings innovative cardiometabolic and rare/orphan disease therapies to market. The transaction is valued at up to approximately $1.1 billion in total equity value on a fully diluted basis, assuming full achievement of certain commercial-based milestones.
As of the deal’s close, shareholders are entitled to receive $3.16 per share in cash, a 58 percent premium to Esperion’s closing price on April 30, 2026, the last trading day prior to the announcement of the transaction. Shareholders will also receive the right to participate in contingent milestone payments of up to $100 million in the aggregate tied to future net sales performance. With the completion of the transaction, Esperion common stock has ceased trading and is no longer listed on the NASDAQ Stock Market. The acquisition vehicle for Esperion is ARCHIMED’s MED Platform II fund.
Founded in 2008 and headquartered in Ann Arbor, Michigan, Esperion is a commercial-stage biopharmaceutical company that initially built its business on non-statin bempedoic acid-based drugs Nexletol and Nexlizet, which reduce low-density lipoproteins in adults with high blood cholesterol, particularly those who are statin-intolerant. In March, Esperion expanded its portfolio with the acquisition of Enbumyst, the first and only FDA-approved nasal spray for edema associated with congestive heart failure, hepatic disease, and renal disease. Esperion reported net revenue of $403 million in 2025.
At Esperion, ARCHIMED will deploy its MedValue template, its levers for accelerating the growth of partnering companies through product range extension, innovation, broader licensing, and acquisitions. Esperion is MED Platform II’s 10th investment; the fund, more than two times oversubscribed, closed on €3.5 billion in June 2023 and is now more than 80 percent invested. Unitranche debt for the transaction was provided by Pharmakon Advisors.
KEY QUOTES:
“We are excited to acquire a strong biopharmaceutical platform with a portfolio of differentiated products used by cardiologists and primary care physicians to address cardiovascular disease and associated conditions.”
Justin Bateman, Partner, ARCHIMED
“This transaction marks a new chapter for Esperion, our employees and the patients and healthcare professionals we serve.”
Sheldon Koenig, CEO, Esperion
